PHVS PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

PHVS ▼ -7.81% at T+5d

NEUTRAL call ✗ call lost -7.81% · α vs SPY -7.89% · entry $31.25 → $28.81

Next anchor: T+20d due 14h ago

Currently $31.60 · +1.12% from $31.25 entry

Entry anchored
May 11, 03:59 PM ET
via Databento tick

T+1d

0.00%

call 0.00% · α -0.54%

$31.25

settled 29d ago

T+5d

-7.81%

call -7.81% · α -7.89%

$28.81

settled 23d ago

T+20d

—

call — · α —

—

due 14h ago

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Pharvaris closed a $132.3M underwritten offering of 4.46M ordinary shares, including full exercise of the underwriters' option. The proceeds provide a significant cash runway for late-stage clinical programs, including the pivotal Phase 3 CHAPTER-3 study for HAE prevention with topline data expected in Q3 2026.

Key Financial Metrics

Deal Value

$132.3M

Actionable Insight

The $132.3M raise provides a multi-year cash runway through key Phase 3 readouts. Monitor Q3 2026 for CHAPTER-3 topline data, which is the primary catalyst. The offering was fully subscribed with underwriter option exercise, indicating strong institutional demand despite dilution.

Key Facts

Closed underwritten offering of 4,455,863 ordinary shares at gross proceeds of ~$132.3M
Underwriters exercised option in full for an additional 581,199 shares
Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities acted as joint book-running managers
Proceeds will fund late-stage clinical programs including CHAPTER-3 Phase 3 study for HAE prevention
Topline data from CHAPTER-3 study anticipated in Q3 2026
CREAATE Phase 3 study for AAE-C1INH is ongoing

Financial Impact

$132.3M gross proceeds from offering

cashdilutionshare count

Risk Factors

Dilution of ~4.5M shares (approximately 10-15% of pre-offering shares outstanding)
Clinical trial risk for CHAPTER-3 and CREAATE studies
No revenue-generating products approved yet

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

90% bullish (20 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3292354

23 reports for PHVS

T+1T+5T+20T+60

80% Hit rate 4 of 5 directional calls best @ T+20▲ +11.42%Mar 20, 2026

Filters

Reports for PHVS — sortable, filterable
	Type				Now
May 29, 2026 11d ago	Press Release NEUTRAL ★ 4/10	$30.16 $31.09	▲ +3.08%	▲ +5.61%	$31.60 (+4.77%)
May 26, 2026 14d ago	Insider Cluster NEUTRAL ★ 4/10	$29.47 $30.14	▲ +2.27%	▲ +1.80%	$31.60 (+7.23%)
May 26, 2026 14d ago	Insider Cluster BEARISH ★ 5/10	$29.47 $30.14	▼ −2.27%	▼ −1.80%	$31.60 (−7.23%)
May 22, 2026 18d ago	Insider Cluster NEUTRAL ★ 3/10	$29.68 $29.10	▼ −1.95%	▼ −3.63%	$31.60 (+6.47%)
May 21, 2026 19d ago	144 NEUTRAL ★ 3/10	$29.68 $29.10	▼ −1.95%	▼ −3.61%	$31.60 (+6.47%)
May 20, 2026 20d ago	Insider Cluster NEUTRAL ★ 3/10	$30.54 $30.16	▼ −1.24%	▼ −3.09%	$31.60 (+3.47%)
May 20, 2026 20d ago	144 NEUTRAL ★ 2/10	$30.54 $30.16	▼ −1.24%	▼ −3.09%	$31.60 (+3.47%)
May 19, 2026 21d ago	Insider Cluster NEUTRAL ★ 4/10	$29.45 $29.86	▲ +1.39%	▼ −0.41%	$31.60 (+7.30%)
May 12, 2026 28d ago	Press Release NEUTRAL ★ 5/10	$32.94 $28.95	▼ −12.11%	▼ −10.95%	$31.60 (−4.07%)
May 11, 2026 29d ago	6-K NEUTRAL ★ 4/10	$31.25 $28.81	▼ −7.81%	▼ −7.89%	$31.60 (+1.12%)

US Market Status

Market Closed — Opens Thu (11h 20m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access